Anti-Human RAGE Recombinant Antibody (XT-M4) (CAT#: TAB-293CT)

Figure 1 Radioactive equivalent concentrations and total radioactivity, as percentage of administered dose (% dose) of [125I]anti-RAGE Ab in serum, lung and spleen of RAGE-/- and wild-type (129S5) mice following a single 5 mg/kg IV dose.

Serum and tissue RE concentrations were monitored by gamma-counting up to ∼5 mo (132 days) in RAGE-/- (open circles) and wild-type (wt) 129S5 (open triangle) mice. The insert in shows serum RE concentrations up to day 9 post-dose. Data show mean ± SD values, with n = 6 per time point. Individual animal concentration values that were less than the limit of quantitation were treated as zero for calculations of the mean and the standard deviation.

Vugmeyster, Y., DeFranco, D., Pittman, D. D., & Xu, X. (2010, September). Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/-mice. In MAbs (Vol. 2, No. 5, pp. 571-575). Taylor & Francis.

Figure 1 Anti-Human RAGE Recombinant Antibody (TAB-293CT) in WB

WB analysis of TAB-293CT was performed by coating with human RAGE protein.
TAB-293CT incubation concentration: 2 ng/μL.
Lane1: Reducing antigen (0.1μg)
Lane1: Reducing antigen (0.3μg)
Lane1: Reducing antigen (0.6μg)
The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 2 Anti-Human RAGE Recombinant Antibody (TAB-293CT) in ELISA

ELISA analysis of TAB-293CT was performed by coating with recombinant human RAGE protein.
The secondary antibody: HRP-Anti-Human IgG (H+L)